Overview
NICE is unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by beta-thalassaemia because BMS did not provide an evidence submission.
Last reviewed: 24 November 2022
Next review: We will review this decision if the company decides to make a submission.